CCRT+TIL

Phase 1Cell therapy

SSun Yat-sen University

CCRT+TIL is one of 35 small molecule programs targeting Cervical Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CarcinomaActive, not recruiting

Cervical CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Cervical Carcinoma

#DrugCompanyPhaseTrials

Camptosar

Taxol

6 3

IC-Green

CCHX Technologies Inc.

Approved

—4

Aldara

BBausch Health Americas, Inc.

Approved

—5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 6

Tecentriq

Paraplatin

3 8

Hycamtin

MMeitheal

Phase 3

3 9

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 10

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cervical Carcinoma1 trial

Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma

Unknown status·SSun Yat-sen University·Phase 1·NCT04443296·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CCRT+TIL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CCRT+TIL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CCRT+TIL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SSun Yat-sen University

CCRT+TIL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cervical Carcinoma1 trial

References

Drug Info

Quick Facts

Related News